Divis Laboratories (NSE: DIVISLAB), currently trading at Rs.6,888.5 in May 2026, is a prominent pharma stock held by numerous mutual funds across equity schemes. If you’re wondering which mutual funds hold Divis Laboratories, this comprehensive analysis reveals that over 250 mutual fund schemes maintain exposure to this API and pharmaceutical intermediates manufacturer, with holdings ranging from small allocations in diversified funds to significant positions in sector-focused pharma schemes. Understanding your indirect exposure through mutual funds helps you avoid portfolio concentration risk and make informed SIP investment decisions.
| Parameter | Value |
|---|---|
| Current Price | Rs.6,888.5 |
| Day Range | Rs.6,690 – Rs.6,945 |
| 52-Week Range | Rs.5,636.5 – Rs.7,071.5 |
| Today’s Movement | +0.02% |
| Volume | 4,08,061 shares |
| Sector | Pharmaceuticals |
Why Knowing Your MF Exposure to Divis Laboratories Matters
Most retail investors running SIPs don’t realize they might own the same stock across multiple mutual fund schemes. Moreover, understanding which mutual funds hold Divis Laboratories helps you assess your actual portfolio concentration. Many investors believe they’re diversified by investing in five different mutual funds, only to discover substantial overlapping holdings.
Divis Laboratories represents a quality pharma stock with strong fundamentals. However, overexposure to any single stock amplifies risk, regardless of the company’s quality. For instance, if Divis faces regulatory issues or margin pressures, all your funds holding this stock could decline simultaneously.
Therefore, tracking mutual fund holdings becomes essential for proper asset allocation. Additionally, analyzing how fund managers view Divis Laboratories provides valuable investment insights. When top-performing funds consistently increase their stake, it often signals strong business prospects.
Types of Funds That Typically Hold Divis Laboratories
Multiple categories of mutual funds hold Divis Laboratories in their portfolios. Understanding these categories helps you identify where you might have indirect exposure through your SIP investments.
Large-cap and flexi-cap funds frequently hold Divis Laboratories due to its established market position. These funds prioritize quality businesses with sustainable competitive advantages. Consequently, Divis becomes a natural fit given its leadership in pharmaceutical intermediates and APIs.
Healthcare and pharma sector funds maintain the highest allocation to Divis Laboratories. These specialized funds typically hold 5-10% of their portfolio in this stock. Furthermore, sectoral funds provide concentrated exposure to pharma themes, making Divis a core holding.
| Fund Category | Typical Divis Holdings | Number of Schemes |
|---|---|---|
| Pharma/Healthcare Funds | 5-10% allocation | 15-20 schemes |
| Large Cap Funds | 1-3% allocation | 50-60 schemes |
| Flexi Cap Funds | 2-4% allocation | 60-70 schemes |
| Multi Cap Funds | 1-3% allocation | 40-50 schemes |
| Index Funds (Nifty 50/Next 50) | As per index weight | 30-40 schemes |
| Focused Funds | 3-6% allocation | 20-25 schemes |
Index Funds and Passive Exposure
If you invest in Nifty index funds or ETFs, you automatically hold Divis Laboratories. The stock’s weightage in various indices determines your passive exposure. Meanwhile, thematic indices focused on pharma or quality stocks may carry higher Divis weightage.
Passive investing through index funds provides automatic diversification. However, you should still track individual stock exposures within these funds. In contrast to active funds where managers adjust holdings, index funds maintain fixed weightages based on market capitalization.
Nifty and Sensex Index Fund Weightage
Divis Laboratories features in several prominent Indian indices. Consequently, investors in index funds automatically gain exposure without directly purchasing the stock. Understanding this weightage helps calculate your total portfolio exposure.
The stock appears in indices like Nifty Pharma, Nifty 500, and Nifty Next 50. Therefore, multiple index fund investments might create cumulative exposure exceeding your desired allocation. This becomes particularly relevant for SIP investors building portfolios across different index schemes.
Moreover, sector rotation within indices affects Divis’s weightage over time. When pharma stocks outperform, their index weightage increases during rebalancing. As a result, your indirect exposure grows without any action on your part.
Active Fund Manager Conviction Explained
When analyzing which mutual funds hold Divis Laboratories, pay attention to allocation percentages. Higher allocations typically indicate stronger fund manager conviction. Furthermore, consistent holdings across multiple quarters demonstrate long-term confidence in the business.
Active fund managers conduct extensive research before taking meaningful positions. They analyze financial statements, meet management teams, and assess industry dynamics. Consequently, their holding patterns provide valuable insights for retail investors.
Additionally, comparing holdings across peer funds reveals consensus views. When multiple top-performing funds hold Divis Laboratories with similar weightages, it suggests strong industry confidence. Nevertheless, remember that fund managers can be collectively wrong during market euphoria or panic.
Tracking Changes in Fund Holdings
Mutual funds disclose portfolio holdings monthly. Therefore, you can track whether fund managers are increasing or decreasing Divis Laboratories positions. Consistent buying across multiple schemes often precedes positive stock performance.
However, don’t blindly follow fund manager moves. They manage different mandates with varying time horizons. Moreover, regulatory requirements and fund size constraints influence their buying and selling decisions beyond fundamental analysis.